



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/589,709	04/12/2007	Charles R. Cantor	701586-054982-US	9508

50607 7590 01/19/2010
RONALD I. EISENSTEIN
100 SUMMER STREET
NIXON PEABODY LLP
BOSTON, MA 02110

EXAMINER

WOOLWINE, SAMUEL C

ART UNIT	PAPER NUMBER
----------	--------------

1637

MAIL DATE	DELIVERY MODE
-----------	---------------

01/19/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10589709	4/12/2007	CANTOR ET AL.	701586-054982-US

RONALD I. EISENSTEIN
100 SUMMER STREET
NIXON PEABODY LLP
BOSTON, MA 02110

EXAMINER

SAMUEL C. WOOLWINE

ART UNIT	PAPER
----------	-------

1637

20100114

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth below:

1. The application does not contain, as a separate part of the disclosure, a "Sequence Listing" as described in 37 CFR 1.821(c);
2. This application does not contain, a copy of the "Sequence Listing" in computer readable form as described in 37 CFR 1.821(e).

Applicant is required to provide the items in 1 and 2 above, an amendment specifically directing entry of the "Sequence Listing" into the application, and a statement that the "Sequence Listing" provided for each of 1 and 2 are the same (37 CFR 1.821(f)) and introduces no new matter (37 CFR 1.821(g)). In lieu of separate copies of the "Sequence Listing" as specified in 37 CFR 1.821(c) and (e), Applicant may file the "Sequence Listing" electronically via EFS-Web (<http://www.uspto.gov/patents/ebs/index.jsp>), in which case the statement under 37 CFR 1.821(f) is not required. Note that the statement under 37 CFR 1.821(g) is still required, as is an amendment directing entry of the "Sequence Listing", even if filed via EFS-Web.

/Samuel Woolwine/
Examiner, Art Unit 1637
January 14, 2010